Thomas Tängdén - Infectious Diseases

Author Information

Thomas Tängdén is a researcher affiliated with the Department of Medical Sciences, Section of Infectious Diseases, at Uppsala University in Sweden. His work primarily focuses on infectious diseases, with a particular interest in antimicrobial resistance and the development of novel diagnostic and therapeutic strategies. Tängdén is recognized for his contributions to understanding microbial infections and advancing antimicrobial stewardship.

Research Contributions

Thomas Tängdén has made significant contributions to the field of infectious diseases, as evidenced by his extensive publication record. His research encompasses a wide range of topics, including antimicrobial stewardship, rapid diagnostic testing, and the treatment of multidrug-resistant bacterial infections. Notably, he has been involved in studies evaluating rapid antibiotic susceptibility testing assays and exploring the interactions of antibiotics with resistant bacterial strains. His work also extends to the development of guidelines for treating infections caused by multidrug-resistant organisms, contributing to global efforts to combat antimicrobial resistance.

Aliases

Thomas Tängdén is also known by the aliases Thomas Tä́ngdén and Thomas Tä́ngden. These variations might appear in different publications or databases.

Publication and Citation Metrics

Metric	Value
Citation Count	2150
h-index	21
Paper Count	59

Publications:

A genome-wide association study in a large community-based cohort identifies multiple loci associated with susceptibility to bacterial and viral infections

DOI: 10.1038/s41598-022-05838-z

Year: 2022

Evaluation of the Speed, Accuracy and Precision of the QuickMIC Rapid Antibiotic Susceptibility Testing Assay With Gram-Negative Bacteria in a Clinical Setting

DOI: 10.3389/fcimb.2022.758262

Year: 2022

An international inventory of antimicrobial stewardship (AMS) training programmes for AMS teams.

DOI: 10.1093/jac/dkab053

Year: 2021

Human plasma protein levels alter the in vitro antifungal activity of caspofungin: An explanation to the effect in critically ill?

DOI: 10.1111/myc.13386

Year: 2021

European Society of clinical microbiology and infectious diseases (ESCMID) guidelines for the treatment of infections caused by Multidrug-resistant Gram-negative bacilli (endorsed by ESICM –European Society of intensive care Medicine)

DOI: 10.1016/j.cmi.2021.11.025

Year: 2021

Interactions of Polymyxin B in Combination with Aztreonam, Minocycline, Meropenem, and Rifampin against Escherichia coli Producing NDM and OXA-48-Group Carbapenemases

DOI: 10.1128/AAC.01065-21

Year: 2021

Evaluation of the speed, accuracy and precision of the QuickMIC rapid antibiotic susceptibility testing assay in a clinical setting

DOI: 10.1101/2021.08.11.455925

Year: 2021

Interactions of polymyxin B in combination with aztreonam, minocycline, meropenem and rifampicin against Escherichia coli producing NDM and OXA-48-group carbapenemases

DOI:

Year: 2021

Blood culture diagnostics: a Nordic multicenter survey comparison of practices in clinical microbiology laboratories.

DOI: 10.1016/j.cmi.2021.09.003

Year: 2021

PRAISE: providing a roadmap for automated infection surveillance in Europe.

DOI: 10.1016/j.cmi.2021.02.028

Year: 2021

How Can Malaria Be Prevented?

What Role Do International Organizations Play?

What is the Treatment for Rabies?

What is the FDA's Role in Public Health Campaigns?

What are the Risks of Untreated Infections During Pregnancy?

What is the Global Impact of Malaria?

What are the future directions in HIV research?

How Does Inflammation Help in Fighting Infections?

How Does Co-Infection Occur?

What Can Be Done to Mitigate These Effects?

Partnered Content Networks

Relevant Topics